
AnaptysBio Investor Relations Material
Latest events

Status Update
AnaptysBio

Q2 2025
6 Aug, 2025

Corporate Presentation
16 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AnaptysBio Inc
Access all reports
AnaptysBio Inc is a clinical-stage biotechnology company. It focuses on developing immunology therapeutics aimed at autoimmune and inflammatory diseases. The company's product pipeline includes several key antibody candidates like Imsidolimab, an anti-IL-36 receptor antibody for treating generalized pustular psoriasis, currently in Phase 3 trials. Another significant product is Rosnilimab, an anti-PD-1 agonist antibody designed to address T-cell driven inflammatory diseases. Additionally, ANB032, an anti-BTLA modulator antibody, is being developed for various human inflammatory diseases linked to immune cell dysregulation. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Key slides for AnaptysBio Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
AnaptysBio Inc


Corporate Presentation
AnaptysBio Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ANAB
Country
🇺🇸 United States